Effect of leucine-rich repeat kinase 2 (LRRK2) on protein synthesis

被引:3
|
作者
Kim, Hyejung [1 ]
Son, Ilhong [1 ,2 ]
Seol, Wongi [1 ]
机构
[1] Wonkwang Univ, InAm Neurosci Res Ctr, Sanbonro 321, Gunposi, Gyeonggido, South Korea
[2] Wonkwang Univ, Dept Neurol, Coll Med, Sanbon Med Ctr, Gunposi, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Protein synthesis; LRRK2; Parkinson's disease; G2019S; kinase; PARKINSONS-DISEASE; PHOSPHORYLATION; AUTOPHAGY; 4E-BP; P53;
D O I
10.1080/19768354.2017.1422803
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in the leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease (PD) in an autosomal dominant manner. Pathogenic mutations of LRRK2 such as G2019S and R1441C have been observed as common genetic causes of PD. Recently, LRRK2 has been reported to increase the reporter protein synthesis in both cap-dependent and -independent manners via phosphorylation of the ribosomal protein RPS15. In this study, we tested whether LRRK2 recombinant protein would directly increase protein synthesis using a well-defined in vitro coupled transcription/translation system. Addition of commercial full-length LRRK2 or GST-fused N-terminal-deleted LRRK2 recombinant proteins to the system showed no change of protein synthesis, as measured by luciferase reporter activity. In addition, the SUnSET assay to measure newly synthesized cellular proteins showed that G2019S overexpression had a minimal effect on the total protein amount. However, we confirmed the previous result that G2019S overexpression increased the amount of protein synthesized from an exogenous gene, Flag-VAMP2, which was transfected as a reporter, whereas there was no significant change in the amount of the Flag-VAMP2 mRNA. Inhibition of protein degradation showed that protein accumulation in the vector control was higher than that of the G2019S overexpression vector. Our results suggest that LRRK2 protein influences the amount of protein by inhibiting protein degradation rather than by directly stimulating translation.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 50 条
  • [31] Cerebrospinal Fluid Biomarkers and Clinical Features in Leucine-Rich Repeat Kinase 2 (LRRK2) Mutation Carriers
    Vilas, Dolores
    Shaw, Leslie M.
    Taylor, Peggy
    Berg, Daniela
    Brockmann, Kathrin
    Aasly, Jan
    Marras, Connie
    Pont-Sunyer, Claustre
    Rios, Jose
    Marek, Ken
    Tolosa, Eduardo
    MOVEMENT DISORDERS, 2016, 31 (06) : 906 - 914
  • [32] Leucine-rich repeat kinase 2 (LRRK2) mRNA expression in the mouse brain: effects of dopamine depletion
    Higashi, S.
    Arai, H.
    Colebrooke, R.
    Ros-Bernal, F.
    Xia, J.
    Lynch, P.
    Herrero, M. T.
    Emson, P. C.
    JOURNAL OF NEUROCHEMISTRY, 2006, 98 : 117 - 117
  • [33] Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors
    Gulati, Anmol
    Yeung, Charles S.
    Lapointe, Blair
    Kattar, Solomon D.
    Gunaydin, Hakan
    Scott, Jack D.
    Childers, Kaleen K.
    Methot, Joey L.
    Simov, Vladimir
    Kurukulasuriya, Ravi
    Pio, Barbara
    Morriello, Greg J.
    Liu, Ping
    Tang, Haiqun
    Neelamkavil, Santhosh
    Wood, Harold B.
    Rada, Vanessa L.
    Ardolino, Michael J.
    Yan, Xin Cindy
    Palte, Rachel
    Otte, Karin
    Faltus, Robert
    Woodhouse, Janice
    Hegde, Laxminarayan G.
    Ciaccio, Paul
    Minnihan, Ellen C.
    DiMauro, Erin F.
    Fell, Matthew J.
    Fuller, Peter H.
    Ellis, J. Michael
    RSC MEDICINAL CHEMISTRY, 2021, 12 (07): : 1164 - 1173
  • [34] Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease
    Julie P. Taylor
    Mary M. Hulihan
    Jennifer M. Kachergus
    Heather L. Melrose
    Sarah J. Lincoln
    Kelly M. Hinkle
    Jeremy T. Stone
    Owen A. Ross
    Robert Hauser
    Jan Aasly
    Thomas Gasser
    Haydeh Payami
    Zbigniew K. Wszolek
    Matthew J. Farrer
    Neurogenetics, 2007, 8 : 95 - 102
  • [35] The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity
    Guo, Luxuan
    Gandhi, Payal N.
    Wang, Wen
    Petersen, Robert B.
    Wilson-Delfosse, Amy L.
    Chen, Shu G.
    EXPERIMENTAL CELL RESEARCH, 2007, 313 (16) : 3658 - 3670
  • [36] Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein
    Yun, HyeJin
    Heo, Hye Young
    Kim, Hyun Ha
    DooKim, Nam
    Seol, Wongi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (10) : 2953 - 2957
  • [37] Leucine-rich repeat kinase 1:: a paralog of LRRK2 and a candidate gene for Parkinson's disease
    Taylor, Julie P.
    Hulihan, Mary M.
    Kachergus, Jennifer M.
    Melrose, Heather L.
    Lincoln, Sarah J.
    Hinkle, Kelly M.
    Stone, Jeremy T.
    Ross, Owen A.
    Hauser, Robert
    Aasly, Jan
    Gasser, Thomas
    Payami, Haydeh
    Wszolek, Zbigniew K.
    Farrer, Matthew J.
    NEUROGENETICS, 2007, 8 (02) : 95 - 102
  • [38] Autophosphorylation in the Leucine-Rich Repeat Kinase 2 (LRRK2) GTPase Domain Modifies Kinase and GTP-Binding Activities
    Webber, Philip J.
    Smith, Archer D.
    Sen, Saurabh
    Renfrow, Matthew B.
    Mobley, James A.
    West, Andrew B.
    JOURNAL OF MOLECULAR BIOLOGY, 2011, 412 (01) : 94 - 110
  • [39] Kinase activity and inhibition of leucine-rich repeat kinase 2 (LRRK2), a common genetic cause of Parkinson's disease
    Greggio, E.
    Lewis, P. A.
    Jain, S.
    Kaganovich, A.
    Ahmad, R.
    Baker, A.
    Beilina, A.
    Cookson, M. R.
    MOVEMENT DISORDERS, 2006, 21 : S603 - S603
  • [40] Leucine-rich repeat kinase 2 (LRRK2) interacts with vacuolar protein sorting 35 (Vps35) to regulate autophagy
    Linhart, R.
    Ho, Y. J.
    Kaing, D.
    Hou, E.
    Sohal, D.
    Eismati, R.
    Rosales, J.
    Fedrizzi, R.
    Tsang, A.
    Fong, D.
    Dawson, A.
    Venderova, K.
    MOVEMENT DISORDERS, 2015, 30 : S406 - S406